The combination of selective inhibition of the cannabinoid CB1-, receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of Spinal Cord Injury

Clinical Neurosurgery

Volumn 56, Issue , 2009, Pages 84-92

  Heller, Joshua E ^a   Baty, Darric E ^a   Zhang, Ming ^a   Li, Hongbo ^a   Adler, Martin ^a   Ganea, Doina ^a   Gaughan, John ^a   Loftus, Christopher M ^a   Jallo, Jack I ^a   Tuma, Ronald F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; NEUROPROTECTIVE AGENT; O 1966; RIMONABANT; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC DYSFUNCTION; BLADDER FUNCTION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RATING SCALE; ROTAROD TEST; SCORING SYSTEM; SPINAL CORD INJURY; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BLADDER; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; MOTOR ACTIVITY; PATHOPHYSIOLOGY;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPINAL CORD INJURIES; URINARY BLADDER;

EID: 77952305841     PISSN: 00694827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Abood ME, Pertwee RG: Cannabinoids. Berlin/New York, Springer, 2005.
2. Alsasua del Valle A: Implication of cannabinoids in neurological diseases. Cell Mol Neurobiol 26:579-591, 2006.
3. Anderberg L, Aldskogius H, Holtz A: Spinal cord injury-Scientific challenges for the unknown future. Ups J Med Sci 112:259-288, 2007.
4. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L, Fezza F, Bisogno T, Di Marzo V: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302, 2001.
5. Basso DM, Beattie MS, Bresnahan JC: Graded histological and locomotor outcomes after spinal cord contusion using the NYU weightdrop device versus transection. Exp Neurol 139:244-256, 1996.
6. Basso DM, Beattie MS, Bresnahan JC, Anderson DK, Faden AI, Gruner JA, Holford TR, Hsu CY, Noble LJ, Nockels R, Perot PL, Salzman SK, Young W: MASCIS evaluation of open field locomotor scores: Effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. J Neurotrauma 13:343-359, 1996.
7. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG: Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 23:635-659, 2006.
8. Baty DE, Zhang M, Li H, Erb CJ, Adler MW, Ganea D, Loftus CM, Jallo JI, Tuma RF: Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury. Clin Neurosurg 55:172-177, 2008.
9. Berdyshev EV: Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 108:169-190, 2000.
10. Bracken MB: Pharmacological interventions for acute spinal cord injury. Cochrane Database Syst Rev (2):CD001046, 2000.
11. Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, Eisenberg HM, Flamm E, Leo-Summers L, Maroon J: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405-1411, 1990.
12. Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL Jr, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W: Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 277:1597-1604, 1997.
13. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F: CB2 receptors in the brain: Role in central immune function. Br J Pharmacol 153:240-251, 2008.
14. Centers for Disease Control and Prevention: http://www.cdc.gov/ncipc/ factsheets/scifacts.htm. Accessed January 17, 2009.
15. Croxford JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17:179-202, 2003.
16. Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L: Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22:6570-6577, 2002.
17. DeVivo MJ: Sir Ludwig Guttmann Lecture: Trends in spinal cord injury rehabilitation outcomes from model systems in the United States: 1973-2006. Spinal Cord 45:713-721, 2007.
18. Dittel BN: Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br J Pharmacol 153:271-276, 2008.
19. Donovan WH: Donald Munro Lecture. Spinal cord injury-Past, present, and future. J Spinal Cord Med 30:85-100, 2007.
20. Guindon J, Hohmann AG: Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334, 2008.
21. Hama A, Sagen J: Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol 204:454-457, 2007.
22. Hurlbert RJ: Strategies of medical intervention in the management of acute spinal cord injury. Spine 31:S16-S21; discussion S36, 2006.
23. Klein TW, Cabral GA: Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1:50-64, 2006.
24. Koopmans GC, Deumens R, Honig WM, Hamers FP, Steinbusch HW, Joosten EA: The assessment of locomotor function in spinal cord injured rats: The importance of objective analysis of coordination. J Neurotrauma 22:214-225, 2005.
25. Lee HC, Cho DY, Lee WY, Chuang HC: Pitfalls in treatment of acute cervical spinal cord injury using high-dose methylprednisolone: A retrospect audit of 111 patients. Surg Neurol 68[Suppl 1]:S37-S41; discussion S41-S32, 2007.
26. Lombard C, Nagarkatti M, Nagarkatti P: CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122:259-270, 2007.
27. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F: CB2 cannabinoid receptor agonists: Pain relief without psychoactive effects? Curr Opin Pharmacol 3:62-67, 2003.
28. Mitchell CS, Lee RH: Pathology dynamics predict spinal cord injury therapeutic success. J Neurotrauma 25:1483-1497, 2008.
29. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ: Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129: 743-750, 2004.
30. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF: Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/ endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10:158-164, 2004.
31. NSCISC: Spinal Cord Injury Facts and Figures at a Glance, 2008.
32. Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462, 2006.
33. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzmán M, Galve-Roperh I: Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20:2405-2407, 2006.
34. van der Stelt M, Veldhuis WB, van Haaften GW, Fezza F, Bisogno T, Bar PR, Veldink GA, Vliegenthart JF, Di Marzo V, Nicolay K: Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21:8765-8771, 2001.
35. Walter L, Stella N: Cannabinoids and neuroinflammation. Br J Pharmacol 141:775-785, 2004.
36. Wolf SA, Ullrich O: Endocannabinoids and the brain immune system: New neurones at the horizon? J Neuroendocrinol 20[Suppl 1]:15-19, 2008.
37. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF: Modulation of the balance between cannabinoid CB1 and CB2 receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152:753-760, 2008.
38. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF: Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia//reperfusion model. J Cereb Blood Flow Metab 27:1387-1396, 2007.